ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
FTSE 100
8,129.21
0.55%
Dow Jones
43,600.80
0.44%
Gold vs US Dollar
2,669.25
0.63%
Brent Oil
73.675
1.15%
Bitcoin
96,419.02
2.18%
Pepperstone
Advertisement
Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. UK
  5. LSE

  6. Aim Immunotech Inc (0A4Y) Share Price

0A4Y Aim Immunotech Inc

0.00
0.00 (0.00%)
Last Updated: -
Delayed by 15 minutes
 Name  Symbol  Market  Type  ISIN  Description 
 Aim Immunotech Inc LSE:0A4Y London Stock Exchange Ordinary Share  AIM IMMUNOTECH ORD SHS
     Change  % Chg  Cur  Bid  Offer  High  Low  Open  Volume  Chg Time
Upgrade Icon
 		 RN  NRN 
   0.00 0.00 0.00 0.00 0.00 0.00 0.00  6,250    
 Sector  Turnover  Profit  EPS - Basic  PE ratio  Mkt Cap 
 Biological Pds,ex Diagnstics 202k -28.96M -0.5930 -3.04 
 Type  Size  Price  Time  Units 
  6,250 15.80 15:19:08 USD
 
Recent News
DateTimeSource
HeadlineMore 0A4Y News
19/09/202412:00UKREGAIM ImmunoTech Reports Positive Preliminary Data in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer
09/05/202412:50UKREGAIM ImmunoTech to Discuss First Quarter 2024 Financial Results on May 16, 2024, and Host Conference Call and Webcast
06/05/202412:30UKREGAIM ImmunoTech Completes cGMP Manufacturing of Clinical Vials of Ampligen®
29/04/202412:55UKREGAIM ImmunoTech Announces First Dose Level is Generally Well-Tolerated in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer
10/04/202412:21UKREGAIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer
02/04/202411:30UKREGAIM ImmunoTech Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
26/03/202413:05UKREGAIM ImmunoTech to Discuss Fourth Quarter and Full Year 2023 Financial Results on April 2, 2024, and Host Conference Call and Webcast
Period
Draw mode
Data Downloads for 0A4Y

Export historical price information open, high, low, close, volume (OHLCV) to Excel

Intraday price data (2 weeks, 1 minute bars)
Technical Analysis for Aim Immunotech Inc
Get quick technical analysis for Aim Immunotech Inc.
Price Indicators
Evaluate in real-time the trend for this stock with base on twelve different studies.
Candlesticks
Verify the trend for the closing and opening times for this stock or defined reversal patterns.
Support & Resistance
Automatically plot the main lines for support and resistance for this tock highlighting the main levels.


Loading Follow Feed...

Latest Aim Immunotech Inc Articles

BLACK FRIDAY

ADVFN

Celebrating 25 years Est 1999-2024

Save up to 60%* for Level 2 Lite

1 year 40%, 2 years 50% and *3 years 60%
EU Flag

*Across 3 years £2132.64 only £853.06